AXQ Capital’s 10x Genomics TXG Stock Holding History

AXQ Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-39,334	Closed	-$460K	–	934
2025 Q3	$460K	Buy	39,334 +8,463	+27%	+$110K	0.18%	205
2025 Q2	$357K	Buy	+30,871	New	+$281K	0.12%	307
2024 Q2	–	Sell	-23,200	Closed	-$871K	–	741
2024 Q1	$871K	Buy	+23,200	New	+$1.02M	0.21%	175
2023 Q4	–	Sell	-6,800	Closed	-$281K	–	806
2023 Q3	$281K	Buy	+6,800	New	+$354K	0.1%	330

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AXQ Capital's TXG Position: Q4 2025 in Review

AXQ Capital sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 39,334 shares — an estimated $460K sold.

AXQ Capital first reported a position in TXG in Q3 2023 and held it in 4 quarters. The position peaked at $871K in Q1 2024. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

AXQ Capital reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
AXQ Capital sold 39,334 10x Genomics shares in Q4 2025, an estimated $460K.
AXQ Capital first reported a position in 10x Genomics in Q3 2023 and held it in 4 quarters.
AXQ Capital's 10x Genomics position peaked at $871K in Q1 2024.
322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on AXQ Capital's 13F filing for Q4 2025, filed 10 Feb 2026.